What is Kratom?
Kratom (Mitragyna speciosa) is a Southeast Asian botanical substance with opioid-like and stimulant properties that the FDA explicitly warns against using, and clinicians should strongly discourage its use due to serious safety concerns including opioid-like toxicity, withdrawal syndrome, hepatotoxicity, seizures, and death. 1
Pharmacologic Profile
Kratom contains over 40 alkaloids, with mitragynine and 7-hydroxymitragynine as the primary active compounds that exert activity at mu-opioid receptors, along with alpha-2 adrenergic agonist effects 2, 3, 4. The pharmacologic effects are dose-dependent:
- Low doses (1-5g): Stimulant effects predominate
- Higher doses (5-15g): Opioid-like sedation and analgesia occur 3, 4
The substance also demonstrates anti-inflammatory properties and acts as both a substrate and inhibitor of the cytochrome P-450 system, creating significant potential for drug interactions 3.
Clinical Harms and Toxicity
Acute Toxicity
Kratom produces opioid-like toxidromes with variable and unpredictable responsiveness to naloxone 2. Critical safety concerns include:
- Respiratory depression that may be delayed or recurrent even after initial naloxone reversal 2
- Central nervous system depression, vomiting, tachycardia 5
- Sedation, obtundation 5
- Seizures, particularly with chronic use 1, 4
Chronic Use Complications
- Hepatotoxicity 4
- Kratom use disorder: Up to 20% of US users report symptoms consistent with substance use disorder 6
- Opioid-like withdrawal syndrome when taking more than 5-15g daily, including irritability, insomnia, muscle aches 1, 6
Product Safety Issues
Commercial kratom products demonstrate substantial variability and frequent mislabeling 7. Products often contain:
- Unreported alkaloids not listed on labels
- Highly potent mu-opioid receptor agonists like 7-hydroxymitragynine
- Inconsistent alkaloid concentrations across batches 7
This manufacturing inconsistency creates unpredictable toxicity risk.
Common Clinical Scenarios
Patients report using kratom for:
- Self-management of chronic pain
- Self-treatment of opioid withdrawal
- Stimulant effects ("legal high") 2, 3, 6
Kratom does not appear on standard urine drug screens, so toxicity may go unrecognized, especially with polysubstance use 3. Many reported deaths involve co-ingestion with other substances 3, 6.
Legal Status
Kratom remains legal at the federal level in the United States but is not FDA-approved for any medical use 1, 4. It is sold as a dietary supplement without regulatory oversight, contributing to the product quality and safety issues described above.
Clinical Management Considerations
Perioperative Management
Discontinue kratom before elective surgery 1. The substance has:
- Opioid agonist properties requiring tapering to prevent withdrawal
- Risk of withdrawal syndrome if abruptly stopped
- Potential for increased anesthetic requirements 1
Acute Toxicity Management
When managing suspected kratom toxicity:
- Administer naloxone for opioid-like symptoms, but anticipate variable response 2
- Extend observation period beyond typical opioid overdose protocols due to risk of delayed or recurrent respiratory depression 2
- Screen for polysubstance use, as most severe cases involve co-ingestants 3, 6
- Consider extended monitoring even after initial naloxone response 2
Withdrawal Management
Treat kratom withdrawal with buprenorphine, particularly in patients with daily high-dose use 6. Withdrawal symptoms mirror opioid withdrawal and respond to standard opioid agonist therapy.
Key Clinical Pitfalls
- Assuming naloxone will reliably reverse toxicity: Response is unpredictable due to complex alkaloid pharmacology 2
- Premature discharge after initial naloxone response: Delayed respiratory depression can occur 2
- Missing the diagnosis: Kratom doesn't appear on standard drug screens 3
- Trusting product labels: Substantial mislabeling and adulteration documented 7